Symptomtext
information on high and low temperature excursions. Products were exposed to a high of 47.4 and a low of 31.4 with no reported adverse event; an ACTHB vaccine was administered to a 5 month-old female, this was after cold excursion of 31.4F with no reported adverse event; Initial information received on 01-Feb-2023 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 5 month old female patient who had taken HIB (PRP/T) VACCINE [ACT-HIB], this was after cold excursion of 31.4f with no reported adverse event and information on high and low temperature excursions. products were exposed to a high of 47.4 and a low of 31.4 with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 31-Jan-2023, the patient received a 0.5 mL (milliliter) dose of suspect HIB (PRP/T) VACCINE (Frequency: once, lot: UJ653AAA, expiry date: 30-Mar-2023) (Strength: not reported) via intramuscular route in unknown administration site for immunization. On 31-Jan-2023, (Latency: same day) the patient developed a non-serious an acthb vaccine was administered to a 5 month old female, this was after cold excursion of 31.4f with no reported adverse event (poor quality product administered) following the administration of HIB (PRP/T) VACCINE. On an unknown date, the HIB (PRP/T) VACCINE information on high and low temperature excursions. products were exposed to a high of 47.4 and a low of 31.4 with no reported adverse event (product storage error) (unknown latency). Action taken: not applicable. It was not reported if the patient received a corrective treatment for the events. At time of reporting, the outcome was Unknown for the events. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.